The piscine retroviruses and their associate neoplasias are new models of oncogenesis. Walleye dermal sarcomas are associated with the presence of a complex retrovirus, walleye dermal sarcoma virus (WDSV). These sarcomas naturally develop and regress making them unique in the study of tumor biology. Walleye dermal sarcoma is transmissible to walleye fingerlings. This transmission is efficient, and disease induction is rapid. Only cell-free homogenates from regressing tumors, not from developing tumors, can transmit disease. Viral-gene expression and proviral burden are also significantly different in developing vs. regressing tumors: Only low levels of spliced accessory gene transcripts are present during tumor development, whereas high levels of all viral transcripts and virus are found in regressing tumors. The accessory genes, named as open reading frames, a, b, and c, presumably function in WDSV biology. The product of orf a is a cyclin homologue or """"""""retroviral cyclin?T. The products of orf b and orf c have no clear homologies. We hypothesize that the accessory proteins are oncogenic, control changes in virus expression, and induce tumor regression. Significant progress has been made in the characterization of both novel and precedented mechanisms involved in these processes. The goals of this proposal are to further characterize the functions of the WDSV accessory proteins in the control of general transcription factors, cell proliferation, and apoptosis. Work will proceed with full characterization of interacting cellular proteins and functional assays of transcription, signal transduction, and mitochondrial targeting. These studies will support the long-term objective of delineating general mechanisms of tumor induction and regression.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA095056-05
Application #
7048518
Study Section
Virology Study Section (VR)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2002-06-01
Project End
2008-05-31
Budget Start
2006-06-01
Budget End
2008-05-31
Support Year
5
Fiscal Year
2006
Total Cost
$233,347
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Microbiology/Immun/Virology
Type
Schools of Veterinary Medicine
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Birkenheuer, Claire H; Brewster, Connie D; Quackenbush, Sandra L et al. (2015) Retroviral cyclin controls cyclin-dependent kinase 8-mediated transcription elongation and reinitiation. J Virol 89:5450-61
Rovnak, Joel; Brewster, Connie D; Quackenbush, Sandra L (2012) Retroviral cyclin enhances cyclin-dependent kinase-8 activity. J Virol 86:5742-51
Paul, Thomas A; Rovnak, Joel; Quackenbush, Sandra L et al. (2011) Transgenic expression of walleye dermal sarcoma virus rv-cyclin (orfA) in zebrafish does not result in tissue proliferation. Mar Biotechnol (NY) 13:142-50
Brewster, Connie D; Birkenheuer, Claire H; Vogt, Megan B et al. (2011) The retroviral cyclin of walleye dermal sarcoma virus binds cyclin-dependent kinases 3 and 8. Virology 409:299-307
Rovnak, Joel; Quackenbush, Sandra L (2010) Walleye dermal sarcoma virus: molecular biology and oncogenesis. Viruses 2:1984-99
Quackenbush, Sandra L; Linton, Ashley; Brewster, Connie D et al. (2009) Walleye dermal sarcoma virus rv-cyclin inhibits NF-kappaB-dependent transcription. Virology 386:55-60
Daniels, Candelaria C; Rovnak, Joel; Quackenbush, Sandra L (2008) Walleye dermal sarcoma virus Orf B functions through receptor for activated C kinase (RACK1) and protein kinase C. Virology 375:550-60
Rovnak, Joel; Casey, Rufina N; Brewster, Connie D et al. (2007) Establishment of productively infected walleye dermal sarcoma explant cells. J Gen Virol 88:2583-9
Rovnak, Joel; Quackenbush, Sandra L (2006) Walleye dermal sarcoma virus retroviral cyclin directly contacts TAF9. J Virol 80:12041-8
Rovnak, Joel; Hronek, Brett W; Ryan, Sean O et al. (2005) An activation domain within the walleye dermal sarcoma virus retroviral cyclin protein is essential for inhibition of the viral promoter. Virology 342:240-51